
Emeis S.A (EMEIS) | Financial Analysis & Statements
Emeis S.A. | Large-cap | Healthcare
Emeis S.A. | Large-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
13.4B
Total Liabilities
11.7B
Shareholders Equity
1.7B
Debt to Equity
6.79
Cash Flow Metrics
Revenue & Profitability Trend
Emeis S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 5.6B | 5.2B | 4.7B | 4.3B | 3.9B |
Cost of Goods Sold | 1.1B | 1.1B | 939.3M | 731.8M | 748.8M |
Gross Profit | 4.5B | 4.1B | 3.7B | 3.6B | 3.2B |
Gross Margin % | 80.0% | 79.4% | 79.9% | 83.0% | 80.9% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | - | - |
Other Operating Expenses | 291.3M | 303.1M | 717.0M | 250.5M | 138.3M |
Total Operating Expenses | 291.3M | 303.1M | 717.0M | 250.5M | 138.3M |
Operating Income | 4.2M | -120.7M | -664.3M | 364.6M | 426.4M |
Operating Margin % | 0.1% | -2.3% | -14.2% | 8.5% | 10.9% |
Non-Operating Items | |||||
Interest Income | 15.2M | 10.0M | 261.0K | 433.0K | 386.0K |
Interest Expense | 398.9M | 581.7M | 334.1M | 210.5M | 228.2M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -360.0M | 1.4B | -4.6B | 105.8M | 210.3M |
Income Tax | 28.6M | 44.6M | -596.5M | 37.5M | 52.6M |
Effective Tax Rate % | 0.0% | 3.2% | 0.0% | 35.5% | 25.0% |
Net Income | -415.5M | 1.4B | -4.0B | 66.9M | 159.3M |
Net Margin % | -7.4% | 26.2% | -86.0% | 1.6% | 4.1% |
Key Metrics | |||||
EBITDA | 718.7M | 3.6B | 141.1M | 1.0B | 930.4M |
EPS (Basic) | - | €10,440.00 | €-3,979.98 | €64.50 | €158.38 |
EPS (Diluted) | - | €10,440.00 | €-3,979.98 | €60.67 | €155.83 |
Basic Shares Outstanding | - | 129809 | 1011825 | 1011182 | 1011137 |
Diluted Shares Outstanding | - | 129809 | 1011825 | 1011182 | 1011137 |
Income Statement Trend
Emeis S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 518.7M | 645.0M | 856.4M | 952.4M | 888.8M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 524.0M | 518.1M | 455.4M | 431.6M | 233.2M |
Inventory | 16.2M | 15.6M | 16.1M | 15.7M | 19.8M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 1.9B | 2.4B | 2.3B | 2.8B | 2.4B |
Non-Current Assets | |||||
Property, Plant & Equipment | 11.0B | 11.3B | 11.5B | 10.5B | 10.9B |
Goodwill | 4.3B | 4.3B | 4.3B | 6.4B | 5.9B |
Intangible Assets | 1.7B | 1.5B | 1.6B | 3.1B | 2.9B |
Long-term Investments | 398.0K | 24.2M | 84.4M | 0 | - |
Other Non-Current Assets | -3.0K | - | -3.0K | 1.0K | 1.0K |
Total Non-Current Assets | 11.5B | 11.5B | 12.2B | 14.3B | 14.6B |
Total Assets | 13.4B | 13.9B | 14.5B | 17.1B | 17.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 405.8M | 502.3M | 327.0M | 334.8M | 310.4M |
Short-term Debt | 882.2M | 1.3B | 8.6B | 2.2B | 1.3B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 425.0M | 424.6M | 336.4M | 412.8M | 422.5M |
Total Current Liabilities | 2.6B | 3.1B | 10.0B | 3.5B | 2.6B |
Non-Current Liabilities | |||||
Long-term Debt | 8.0B | 7.9B | 4.8B | 10.0B | 9.2B |
Deferred Tax Liabilities | 730.7M | 662.5M | 814.0M | 997.0M | 1.4B |
Other Non-Current Liabilities | -2.0K | -2.0K | - | 2.0K | 2.0K |
Total Non-Current Liabilities | 9.1B | 8.9B | 6.0B | 11.2B | 10.8B |
Total Liabilities | 11.7B | 12.0B | 16.0B | 14.7B | 13.5B |
Equity | |||||
Common Stock | 1.6M | 1.3B | 80.9M | 80.8M | 80.8M |
Retained Earnings | -412.1M | 1.4B | -4.0B | 65.2M | 160.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.7B | 1.9B | -1.5B | 2.3B | 3.5B |
Key Metrics | |||||
Total Debt | 8.9B | 9.2B | 13.4B | 12.1B | 10.5B |
Working Capital | -743.4M | -751.5M | -7.7B | -738.1M | -223.2M |
Balance Sheet Composition
Emeis S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -415.5M | 1.4B | -4.0B | 66.9M | 160.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -80.0M | -148.2M | -262.1M | -218.1M | -106.6M |
Operating Cash Flow | 27.4M | -467.9M | -102.5M | 677.0M | 693.9M |
Investing Activities | |||||
Capital Expenditures | -143.4M | -141.0M | -136.3M | - | - |
Acquisitions | -100.2M | -8.2M | -28.7M | -421.9M | -494.4M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -243.7M | -149.2M | -165.0M | -421.9M | -988.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | -58.2M | - |
Debt Issuance | 201.3M | 500.0M | 3.4B | 2.3B | 1.7B |
Debt Repayment | -273.2M | -972.0M | -2.5B | -991.9M | -933.5M |
Financing Cash Flow | 318.4M | 688.1M | 898.4M | 1.3B | 811.0M |
Free Cash Flow | 328.6M | 225.1M | 273.4M | 753.8M | 777.7M |
Net Change in Cash | 102.1M | 71.0M | 630.9M | 1.5B | 516.0M |
Cash Flow Trend
Emeis S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
0.02
Forward P/E
-640.50
Price to Book
1.20
Price to Sales
0.37
PEG Ratio
-640.50
Profitability Ratios
Profit Margin
-7.31%
Operating Margin
0.54%
Return on Equity
-23.02%
Return on Assets
0.01%
Financial Health
Current Ratio
0.72
Debt to Equity
514.45
Beta
0.68
Per Share Data
EPS (TTM)
€-2.62
Book Value per Share
€10.71
Revenue per Share
€35.81
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
emeis | 2.1B | 0.02 | 1.20 | -23.02% | -7.31% | 514.45 |
Orpea | 2.0B | 0.10 | 0.85 | 704.66% | 26.07% | 485.11 |
Clariene SE | 1.6B | 9.76 | 0.43 | -1.54% | -1.16% | 209.58 |
Ramsay Générale de | 1.1B | 34.13 | 0.99 | -5.16% | -1.55% | 337.92 |
Lna Santé S.A | 286.3M | 13.10 | 0.91 | 7.25% | 2.71% | 270.87 |
EssilorLuxottica | 118.0B | 48.88 | 3.07 | 6.44% | 8.74% | 36.58 |
Financial data is updated regularly. All figures are in the company's reporting currency.